3 blue chip ASX 200 shares experts say are buys

growth ASX shares, small caps

growth ASX shares, small caps

The ASX 200 index is home to a good number of blue chip shares. But which of these shares would make good additions to a portfolio this week?

Three blue chip shares that are highly rated are listed below. Here’s what experts are saying about them:

CSL Limited (ASX: CSL)

The first blue chip share to look at is CSL. It is a leading biotherapeutics company which owns the CSL Behring and Seqirus businesses. Combined, these two businesses have a portfolio of life-saving and lucrative therapies and vaccines which are generating billions of dollars in sales each year. But management isn’t resting on its laurels. Each year the company invests in the region of 10% to 11% of its sales back into research and development activities every year. This means it is on course to invest ~US$1 billion into these activities this year. This ensures that CSL has a pipeline of potentially lucrative products to support its long term growth.

Analysts at Citi are big fans of the company. The broker currently has a buy rating and $330.00 price target on its shares.

REA Group Limited (ASX: REA)

Another ASX 200 blue share to look at is REA Group. It is the dominant player in real estate listings in the Australian market. In fact, in the first half of FY 2022, during one month the company saw 13.2 million people visit its local site. This is the equivalent of 65% of Australia’s adult population. Furthermore, on average, there were 3.3x more visits than the nearest competitor each month. Thanks to this leadership position, new revenue streams, acquisitions, price increases, and its international operations, the company has been tipped to continue its solid growth in the coming years.

Goldman Sachs remains very positive on REA Group. Its analysts currently have a buy rating and $164.00 price target on its shares.

ResMed Inc. (ASX: RMD)

A final blue chip ASX 200 share to look at is ResMed. It is a medical device company with a focus on the growing sleep treatment market. Thanks to its industry-leading products, wide distribution network, and successful acquisitions, ResMed has been growing at a very strong rate over the last few years. Pleasingly, thanks to its significant market opportunity and the growing prevalence of sleep disorders, analysts are tipping the company to continue its growth for the foreseeable future.

Morgans is bullish and has an add rating and $37.95 price target on its shares.

The post 3 blue chip ASX 200 shares experts say are buys appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

See The 5 Stocks
*Returns as of July 7 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. and ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool Australia has recommended REA Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/IzrGDKM

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s